ImmunityBio报告第二季度收入高于预期

2025-07-25 18:07

ImmunityBio press release (NASDAQ:IBRX): Q2 revenue of $26.4M (+60.0% Q/Q) beats by $4.45M.

More on ImmunityBio

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
ImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial Pressures
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva
ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success